Financial Comparison: Adyen (OTCMKTS:ADYEY) versus Orion Oyj (OTCMKTS:ORINY)

Adyen (OTCMKTS:ADYEY) and Orion Oyj (OTCMKTS:ORINY) are both computer and technology companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, earnings, dividends, risk, institutional ownership, profitability and valuation.

Earnings and Valuation

This table compares Adyen and Orion Oyj”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adyen	$2.02 billion	22.91	$755.73 million	N/A	N/A
Orion Oyj	$1.29 billion	5.13	$234.64 million	$1.26	18.57

Adyen has higher revenue and earnings than Orion Oyj.

Profitability

This table compares Adyen and Orion Oyj’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Adyen	N/A	N/A	N/A
Orion Oyj	23.01%	41.41%	22.43%

Volatility and Risk

Adyen has a beta of 2.57, indicating that its stock price is 157% more volatile than the S&P 500. Comparatively, Orion Oyj has a beta of 0.21, indicating that its stock price is 79% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Adyen and Orion Oyj, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adyen	0	0	0	2	4.00
Orion Oyj	0	0	0	0	0.00

Institutional and Insider Ownership

0.1% of Adyen shares are owned by institutional investors. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Adyen beats Orion Oyj on 7 of the 10 factors compared between the two stocks.

About Adyen

Adyen N.V. operates a payments platform in Europe, the Middle East, Africa, North America, the Asia Pacific, Latin America. The company's platform integrates payments stack that include gateway, risk management, processing, issuing, acquiring, and settlement services. It offers a back-end infrastructure for authorizing. It serves digital, mobility, platforms and marketplace, retail, food and beverages, subscription, and hospital businesses. Adyen N.V. was incorporated in 2006 and is headquartered in Amsterdam, the Netherlands.

About Orion Oyj

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides prescription drugs and self-care products, which includes Nubeqa for the treatment of prostate cancer; Precedex, Dexdor, and Precedex for human use; Burana for inflammatory pain; Divina series for menopausal symptoms; Trexan for rheumatoid arthritis and cancer; Stalevo, Entacapone, and Comtess/Comtan for Parkinson’s disease; Biosimilars for rheumatoid arthritis and inflammatory bowel diseases; and Simdax for acute decompensated heart failure, as well as Fareston for breast cancer. It also offers Salmeterol/fluticasone Easyhaler, Budesonide/formoterol Easyhaler, Formoterol Easyhaler, Budesonide Easyhaler, Beclomet Easyhaler, and Buventol Easyhaler drugs for the treatment of asthma and chronic obstructive pulmonary disease. In addition, the company provides veterinary drugs comprising Bonqat, Clevor, Domosedan, Domitor, Antisedan, Dexdomitor, Domosedan Gel, Sileo, and Tessie; APIs for generic compounds and proprietary products, as well as contract manufacturing services; and markets and sells veterinary drugs manufactured by other international companies. Further, the company has partnership with Propeller Health to connect the Easyhaler(R) product portfolio; and a research collaboration and license agreement with Amneal Pharmaceuticals, Inc. to commercialize Amneal’s generic products. Orion Oyj was founded in 1917 and is headquartered in Espoo, Finland.